Body Surface Area-Weighted Left Ventricular Ejection Fraction Enhances Prediction Accuracy of OPCABG Outcomes: A Large Multi-Center Cohort Study

体表面积加权左心室射血分数可提高非体外循环冠状动脉旁路移植术(OPCABG)预后的预测准确性:一项大型多中心队列研究

阅读:1

Abstract

BACKGROUND: We hypothesized that body surface area (BSA)-weighted left ventricular ejection fraction (LVEF) (bLVEF) would represent a superior predictor of mortality in off-pump coronary artery bypass grafting (OPCABG) patients than standard predictors. LVEF is associated with worse outcomes upon OPCABG, while referring left ventricular measurements to BSA should improve predictability. METHODS: The bLVEF was calculated by multiplying the LVEF by the BSA. The primary endpoint was all-cause mortality within 30 days of hospitalization, while secondary endpoints included major postoperative complications. RESULTS: A total of 7927 patients from five leading cardiac centers participating in the Chinese Cardiac Surgery Registry were included in the final analysis, of which 7093 (89.48%) had normal LVEF, 639 (8.06%) presented heart failure with mid-range ejection fraction (HFmrEF), and 195 (2.46%) exhibited heart failure with reduced ejection fraction (HFrEF). The average bLVEF in the cohort was 109.63 ± 18.16. Both the mortality (odds ratio (OR) 0.97) and secondary endpoints (OR 0.97) followed a similar trend with increasing bLVEF, indicating that bLVEF is a more reliable predictor of adverse outcomes. The individual components of bLVEF, including BSA (area under the curve (AUC) 0.63) and LVEF (AUC 0.64), made minor contributions to mortality risk with relatively low AUC values. However, these components were less impactful than bLVEF (AUC 0.70). Notably, patients with a bLVEF less than 85 had an increased mortality risk relative to those whose bLVEF was 85 or higher (adjusted OR 4.65 (95% confidence interval (CI): 3.81-5.83; p < 0.01)). CONCLUSION: The bLVEF serves as a key predictor of mortality in OPCABG patients, effectively eliminating BSA-related bias and demonstrating a strong capacity to predict mortality. CLINICAL TRIAL REGISTRATION: NCT02400125, https://www.clinicaltrials.gov/study/NCT02400125.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。